Status:
COMPLETED
A Clinical Trial to Investigate the Influence of CES1 Polymorphism on Oseltamivir
Lead Sponsor:
Seoul National University Hospital
Conditions:
Healthy
Eligibility:
All Genders
20-45 years
Phase:
PHASE1
Brief Summary
Investigate genetic variability of CES1 gene on pharmacokinetics of oseltamivir in healthy Korean volunteers.
Eligibility Criteria
Inclusion
- Healthy subjects:
- Agreement with written informed consent
- Adult healthy male or female subject age 20 to 45
Exclusion
- Clinically significant, active gastrointestinal system, cardiovascular system, pulmonary system, renal system, endocrine system, blood system, digestive system, central nervous system, mental disease or malignancy
- Medication with any drug which may affect the pharmacokinetics of oseltamivir within 14 days
- Previously donate whole blood within 30 days or Previously participated in other trial within 60 days
- Subject with known for hypersensitivity reactions to oseltamivir
- Subject who perform contraception during study periods
- Female woman who are pregnant or are breast feeding
- An impossible one who participates in clinical trial by investigator's decision including laboratory test result
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01902342
Start Date
July 1 2013
End Date
December 1 2013
Last Update
May 19 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital Clinical Trial Center
Seoul, South Korea, 110-768